

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 77326

Title: A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03674832

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Greece

Author's Country/Territory: France

Manuscript submission date: 2022-04-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-09 04:41

Reviewer performed review: 2022-05-10 06:54

Review time: 1 Day and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous
	Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No

SPECIFIC COMMENTS TO AUTHORS

Evaluation of the paper 77326 A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena. The aim of the study was to summarize evidence which associate SGLT2i and ischemia/reperfusion injuries, by first listing known mechanisms which portend the latter, and second, hypothesize how the former may interact with these mechanisms. The authors conclude that beyond the cardiovascular benefits observed in patients with chronic heart failure treated by SGLT2i, data from large clinical trials including EMPA-REG or DAPA-HF may suggest a benefit through ischemia-reperfusion events. The inhibition of the Na⁺/H⁺ exchanger may play a pivotal role in such cardioprotective feature and further investigations towards the immunomodulatory properties of SGLT2i drug-class are warranted. Comments 1. This is a well written paper with a theory of the way action of SGLT2i and induction of clinical benefit. 2. The text and the figures are satisfactory and informative. 3. References are up-to-date, however the following reference might improve the paper: - Zuurbier CJ. Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels? *Cardiovasc Diabetol*. 2020 Sep 19;19(1):141. - Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. *J Endocrinol*. 2018 Feb;236(2):69-84. 4. The conclusions of the paper has practical implications.

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 77326

Title: A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03835933

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: India

Author's Country/Territory: France

Manuscript submission date: 2022-04-25

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-09 05:17

Reviewer performed review: 2022-05-11 12:34

Review time: 2 Days and 7 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input checked="" type="checkbox"/>] Yes [<input type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The authors must be complimented for selecting a crucial but lesser understood topic, for a review. The efforts for the review are thorough and commendable. A few aspects may be further considered, for giving a more holistic understanding, based on the current knowledge.